Linezolid pharmacokinetics in pediatric patients: An overview

Pediatric Infectious Disease Journal

Volumn 22, Issue 9 SUPPL., 2003, Pages

  Jungbluth, Gail L ^a   Welshman, Ian R ^a   Hopkins, Nancy K ^a  

^a PFIZER INC   (United States)

Author keywords

Dosage and administration; Linezolid; Pediatrics; Pharmacokinetics

Indexed keywords

LINEZOLID;

ADOLESCENT; ADULT; AGE; AREA UNDER THE CURVE; BACTERIAL INFECTION; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; GRAM POSITIVE BACTERIUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; MASS SPECTROMETRY; PRIORITY JOURNAL; REVIEW;

EID: 0141792776     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000086954.43010.63     Document Type: Review

References (26)

1. Kearns GL. Impact of developmental pharmacology on pediatric study design: overcoming the challenges. J Allergy Clin Immunol 2000;106:S128-38.
2. San Joaquin VH, Stull TL. Antibacterial agents in pediatrics. Infect Dis Clin North Am 2000;14:341-55.
3. Singh J, Burr B, Stringham D, Arrieta A. Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics. Paediatr Drugs 2001;3:733-61.
4. Skaer TL. Dosing considerations in the pediatric patient. Clin Ther 1991;13:526-44.
5. Johnson RA, Haan DE, James CA, Hopkins NK. Determination of linezolid, PNU-100766, in human plasma and urine using high-performance liquid chromatography with ultraviolet detection. Pharm Res 1997;14(Suppl):S-374.
6. Welshman IR, Sisson TA, Jungbluth GL, Stalker DJ, Hopkins NK. Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm Drug Dispos 2001;22:91-7.
7. Stalker DJ, Jungbluth GL, Hopkins NK, Batts DH. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 2003;51:1239-46.
8. Moellering RC Jr. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003;138:135-42.
9. Zyvox (linezolid) [prescribing information]. Kalamazoo, MI: Pharmacia and Upjohn Company, 2002.
10. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003;51(Suppl 2):ii17-25.
11. Gee T, Ellis R, Marshall G, Andrews J, Ashb J, Wise R. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001;45:1843-6.
12. Hachem R, Afif C, Gokaslan Z, Raad I. Successful treatment of vancomycin-resistant Enterococcus meningitis with linezolid. Eur J Clin Microbiol Infect Dis 2001;20:432-4.
13. Conte JE Jr., Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002;46:1475-80.
14. Lovering AM, Zhang J, Bannister GC, et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002;50:73-7.
15. Wynalda MA, Hauer MJ, Wienkers LC. Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes. Drug Metab Dispos 2000;28:1014-7.
16. 14C] linezolid to healthy human subjects. Drug Metab Dispos 2001;29:1136-45.
17. Lasher-Sisson T, Jungbluth GL, Hopkins NK. Age and sex effects on the pharmacokinetics of linezolid. Eur J Clin Pharmacol 2002;57:793-7.
18. Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with varying degrees of renal function and on dialysis. J Invest Med 1998;46:276A.
19. Hendershot PE, Jungbluth GL, Cammarata SK, Hopkins NK. Pharmacokinetics of linezolid in patients with liver diseases. J Antimicrob Chemother 1999;44(Suppl A):55.
20. Hopkins NK, Johnson RA, Jungbluth GL, Glavanovich MA. Quantitation of linezolid (ZYVOX™, PNU-100766) and two of its primary metabolites in human plasma by step gradient HPLC/MS/MS. Presented at the American Society for Mass Spectrometry's 51st Annual Conference on Mass Spectrometry and Allied Topics, Montreal, June 8 to 12, 2003.
21. Kearns GL, Abdel-Rahman SM, Blumer JL, et al., and the Pediatric Pharmacology Research Unit Network. Single dose pharmacokinetics of linezolid in infants and children. Pediatr Infect Dis J 2000;19:1178-84.
22. Jungbluth GL, Welshman IR, Hopkins NK, Bruss JB, Wu E, Kearns GL. Impact of gestational and postnatal age on linezolid disposition in neonates and young infants. Presented at the Pediatric Academic Societies Annual Meeting, Baltimore, May 4 to 7, 2002.
23. Vo M, Rubino C, Cirincione B, Bruss J, Jungbluth GL. Pharmacokinetic-pharmacodynamic analysis of data from a Phase III trial of linezolid iv/po for the treatment of resistant Gram-positive bacterial infections in children [Abstract]. Clin Pharmacol Ther 2003;73:74.
24. Rubino CM, McPhee ME, Jungbluth GL. Application of real-time data assembly (RTDA) to a pivotal Phase III pediatric trial: a proactive approach to population pharmacokinetic/pharmacodynamic (PK/PD) dataset creation [Abstract]. Clin Pharmacol Ther 2003;73:65.
25. Jungbluth GL, Welshman IR, Hopkins NK, Bruss JB, James LP, Kearns GL. Linezolid pharmacokinetics in adolescents. Presented at the Pediatric Academic Societies Annual Meeting, Baltimore, May 4 to 7, 2002.
26. Andes D, van Ogtrop ML, Peng J, Craig WA. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002;46:3484-9.